FDA OKs GLP‑1 pill
- The FDA approved an oral form of semaglutide, marking the first GLP‑1 pill approved for weight loss. - The approval was reported as oral semaglutide becoming the first GLP‑1 pill option similar to Wegovy. - This approval could broaden access beyond injections and change how people pursue medical weight-loss strategies (ajmc.com).
Semaglutide, the appetite-slowing drug behind Wegovy shots, is now also an FDA-approved weight-loss pill in the U.S. (ajmc.com) The newly approved product is a tablet form of Wegovy, making it the first oral glucagon-like peptide 1, or GLP-1, medicine cleared for chronic weight management. Novo Nordisk’s obesity-pipeline materials and FDA-linked labeling identify the tablet as oral semaglutide. (ajmc.com) (accessdata.fda.gov) GLP-1 drugs copy a gut hormone that helps people feel full and eat less. The pill gives patients a daily alternative to Wegovy’s once-weekly injection. (novonordisk.com) (drugs.com) In the phase 3 OASIS 4 trial cited in coverage of the approval, adults taking oral semaglutide lost an average 13.6% of body weight over 64 weeks, versus 2.2% with placebo. The study enrolled 307 adults with obesity or overweight. (ajmc.com) The approval extends a drug class that had already moved from diabetes into obesity, heart-risk reduction, and liver disease. Wegovy injection was first approved for weight loss in 2021, and FDA materials now show Wegovy in both injection and tablet forms. (drugs.com) (accessdata.fda.gov) Novo Nordisk had already sold oral semaglutide as Rybelsus for type 2 diabetes before pursuing a higher-dose obesity version. Company materials say the diabetes pill launched in 2019 and described the obesity tablet as the first oral GLP-1 approved for weight management in the U.S. in 2025. (novonordisk.com) A pill does not remove the access fights around these drugs. AJMC reported that payers and employers still face high spending, and it said the oral option expands treatment choice without automatically lowering cost. (ajmc.com) The label carries the same boxed warning long attached to semaglutide products about thyroid C-cell tumors seen in rodents. FDA-linked prescribing information also says the tablet can raise exposure to some oral medicines, including levothyroxine. (accessdata.fda.gov) That leaves the biggest immediate change in the form, not the mechanism: the same semaglutide franchise that reshaped obesity treatment now comes in a pill bottle as well as an injection pen. (accessdata.fda.gov) (drugs.com)
